Discovery of new 1,4-disubstituted 1,2,3-triazoles: in silico ADME profiling, molecular docking and biological evaluation studies


Sahin I., ÇEŞME M., YÜCE N., TÜMER F.

JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, cilt.41, sa.5, ss.1988-2001, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 5
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1080/07391102.2022.2025905
  • Dergi Adı: JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1988-2001
  • Anahtar Kelimeler: Triazoles, anticancer, antioxidant activity, alpha-amylase inhibition, in silico, molecular docking, ADME, ANTIOXIDANT ACTIVITY, ANTIMICROBIAL ACTIVITY, DERIVATIVES DESIGN, INHIBITORS, ANTICANCER, ACID
  • Atatürk Üniversitesi Adresli: Evet

Özet

In this work, eight new 1,2,3-triazoles (6a-h) were synthesized from acetylenes' "click" reaction with p-substituted azide derivatives. The structures of the compounds were characterized using standard analytical and spectroscopic methods (elemental analysis, FT-IR, H-1(C-13)NMR). The anticancer, antioxidant, alpha-amylase, ADME, molecular docking studies of synthesized triazoles were investigated. According to alpha -amylase enzyme inhibition results, all compounds except 6c (IC50: 2299 mu g/mL) were found to have a higher IC50 value than the standard drug acarbose (IC50: 891 mu g/mL). Compound 6g (IC50: 68 mu g/mL) exhibited 13 times higher activity than standard acarbose. All compounds, except 6e, have been shown to have greater DPPH radical scavenging capabilities than BHT and beta-carotene standards. According to ABTS radical scavenging studies, all compounds showed higher scavenging activity than ascorbic acid and Trolox. To determine the anticancer activity of the synthesized compounds, they were screened against the Hela cell line, and the results were compared with standard cisplatin (IC50: 16.30 mu g/mL). Compound 6a (IC50: 49.03 mu g/mL) was determined to have moderate activity relative to cisplatin. The compounds were examined comprehensively for ADME characteristics and did not violate any drug-likeness rule. ADME data showed that all physicochemical and pharmacological parameters of the compounds remained within defined limits as specified in Lipinski's rules (RO5) and put forth a high bioavailability profile. The molecular docking findings show that all molecules have a high affinity by exhibiting polar and apolar contact with essential residues in the binding pocket of alpha-amylase.